BR112018013995A2 - terapia de combinação de vírus oncolítico e inibidor de ponto de verificação - Google Patents
terapia de combinação de vírus oncolítico e inibidor de ponto de verificaçãoInfo
- Publication number
- BR112018013995A2 BR112018013995A2 BR112018013995A BR112018013995A BR112018013995A2 BR 112018013995 A2 BR112018013995 A2 BR 112018013995A2 BR 112018013995 A BR112018013995 A BR 112018013995A BR 112018013995 A BR112018013995 A BR 112018013995A BR 112018013995 A2 BR112018013995 A2 BR 112018013995A2
- Authority
- BR
- Brazil
- Prior art keywords
- checkpoint inhibitor
- oncolytic virus
- combination therapy
- virus combination
- oncolytic
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 2
- 244000309459 oncolytic virus Species 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
- C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
a presente invenção se refere a uma combinação para a utilização simultânea, separada ou sequencial que compreende (a) um vírus oncolítico e (b) um inibidor de ponto de verificação e à sua utilização para o tratamento de câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662277352P | 2016-01-11 | 2016-01-11 | |
PCT/CA2017/050031 WO2017120670A1 (en) | 2016-01-11 | 2017-01-11 | Oncolytic virus and checkpoint inhibitor combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013995A2 true BR112018013995A2 (pt) | 2019-02-05 |
Family
ID=59310481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013995A BR112018013995A2 (pt) | 2016-01-11 | 2017-01-11 | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190022203A1 (pt) |
EP (1) | EP3402500A4 (pt) |
JP (1) | JP2019501205A (pt) |
KR (1) | KR20190038470A (pt) |
CN (1) | CN109069561A (pt) |
AU (1) | AU2017207532A1 (pt) |
BR (1) | BR112018013995A2 (pt) |
CA (1) | CA3011157A1 (pt) |
MX (1) | MX2018008346A (pt) |
WO (1) | WO2017120670A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11382953B2 (en) * | 2016-08-26 | 2022-07-12 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
MA51630A (fr) * | 2017-03-15 | 2020-01-22 | Amgen Inc | Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer |
AR112405A1 (es) * | 2017-08-07 | 2019-10-23 | Amgen Inc | Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas |
WO2019048689A1 (en) | 2017-09-11 | 2019-03-14 | Imba - Institut Für Molekulare Biotechnologie Gmbh | TUMOR ORGANOID MODEL |
KR20200121297A (ko) | 2018-01-05 | 2020-10-23 | 오타와 하스피털 리서치 인스티튜트 | 변형된 오르토폭스바이러스 벡터 |
GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
JP2022510856A (ja) * | 2018-11-23 | 2022-01-28 | ビラ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Vsvキメラベクター |
CN111494432A (zh) * | 2019-01-31 | 2020-08-07 | 惠君生物医药科技(杭州)有限公司 | 一种用于治疗肿瘤或癌症的药物组合物及其应用 |
CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
WO2020223639A1 (en) * | 2019-05-01 | 2020-11-05 | Sensei Biotherapeutics, Inc. | Combination therapies for cancer |
WO2021022155A1 (en) * | 2019-07-31 | 2021-02-04 | Aivita Biomedical, Inc. | Soluble programmed cell death protein-1 as a biomarker in cancer patients |
CN110564767A (zh) * | 2019-08-08 | 2019-12-13 | 董春升 | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 |
AU2019464086A1 (en) * | 2019-08-26 | 2022-02-24 | Bionoxx Inc. | Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients |
KR20210101620A (ko) * | 2020-02-10 | 2021-08-19 | 주식회사 천랩 | 패칼리박테리움 속 균주를 이용한 항암 치료 |
CN111286493B (zh) * | 2020-05-12 | 2020-10-27 | 上海荣瑞医药科技有限公司 | 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物 |
CN111467489B (zh) * | 2020-05-12 | 2022-06-03 | 上海荣瑞医药科技有限公司 | 一种治疗肿瘤的药物 |
TW202214279A (zh) * | 2020-09-18 | 2022-04-16 | 大陸商成都美杰賽爾生物科技有限公司 | 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤 |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
CN113368246B (zh) * | 2021-05-12 | 2023-05-26 | 中山大学 | 一种增效的抗肿瘤药物 |
WO2023159102A1 (en) * | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9707285B2 (en) * | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
CA2901501C (en) * | 2013-02-21 | 2023-03-07 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
JP6581101B2 (ja) * | 2014-02-14 | 2019-09-25 | イミューン デザイン コーポレイション | 局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法 |
EP3119426A4 (en) * | 2014-03-19 | 2018-02-28 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
US10188713B2 (en) * | 2014-03-19 | 2019-01-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3256156A1 (en) * | 2015-02-13 | 2017-12-20 | Transgene SA | Immunotherapeutic vaccine and antibody combination therapy |
-
2017
- 2017-01-11 US US16/069,136 patent/US20190022203A1/en not_active Abandoned
- 2017-01-11 EP EP17738058.1A patent/EP3402500A4/en not_active Withdrawn
- 2017-01-11 MX MX2018008346A patent/MX2018008346A/es unknown
- 2017-01-11 WO PCT/CA2017/050031 patent/WO2017120670A1/en active Application Filing
- 2017-01-11 JP JP2018536150A patent/JP2019501205A/ja active Pending
- 2017-01-11 BR BR112018013995A patent/BR112018013995A2/pt not_active IP Right Cessation
- 2017-01-11 AU AU2017207532A patent/AU2017207532A1/en not_active Abandoned
- 2017-01-11 CN CN201780006365.7A patent/CN109069561A/zh active Pending
- 2017-01-11 CA CA3011157A patent/CA3011157A1/en not_active Abandoned
- 2017-01-11 KR KR1020187023161A patent/KR20190038470A/ko unknown
-
2018
- 2018-08-09 US US16/059,914 patent/US20190070280A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20190038470A (ko) | 2019-04-08 |
EP3402500A4 (en) | 2019-06-12 |
US20190070280A1 (en) | 2019-03-07 |
EP3402500A1 (en) | 2018-11-21 |
CN109069561A (zh) | 2018-12-21 |
JP2019501205A (ja) | 2019-01-17 |
AU2017207532A1 (en) | 2018-08-16 |
US20190022203A1 (en) | 2019-01-24 |
WO2017120670A1 (en) | 2017-07-20 |
MX2018008346A (es) | 2019-07-04 |
CA3011157A1 (en) | 2017-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
UY37155A (es) | Inhibidores de ret | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
BR112016015399A2 (pt) | método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico | |
CR20160538A (es) | Combinación | |
CR20170219A (es) | Inhibidores del bromodominio | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
EP4286009A3 (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
DK3740504T3 (da) | CD70 kombinationsterapi | |
BR112018008103A2 (pt) | análogos de celastrol | |
BR112018069927A2 (pt) | terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação | |
CO2018013020A2 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
BR112018013272A2 (pt) | composições e métodos para detectar e tratar câncer esofágico | |
BR112017023855A2 (pt) | o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc) | |
BR112017019841A2 (pt) | técnica de análise de amostra de tecido | |
BR112018013268A2 (pt) | composições e métodos para detectar e tratar câncer gástrico | |
CO2017002356A2 (es) | Métodos para tratar la depresión usando moduladores de nmda |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2705 DE 08-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |